Compare Lowe`s Companies Inc (LOW) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lowe`s Companies Inc vs GeneDx Holdings Corp — how do they compare? Lowe`s Companies Inc trades at $203.77 (market cap $114.78B), while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: Lowe`s Companies Inc is far larger — about 63.8× GeneDx Holdings Corp's market cap, and Lowe`s Companies Inc pays a 2.44% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| LOW | WGS | |
|---|---|---|
Market Cap | $114.78B | $1.80B |
Sector | Consumer Cyclical | Technology |
52-Week High | $287.39 | $167.51 |
52-Week Low | $204.76 | $34.51 |
Enterprise Value | $156.54B | $1.80B |
Dividend Yield | 2.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lowe's Companies (LOW) trades at $203.52, down 2.5% over the past day, amid a bearish technical signal. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS expected at $4.26. Revenue declined to $83.67 billion in 2025, but net income margin remains healthy at 7.51%. Analyst consensus is strongly bullish with a $260.88 price target, though technical indicators show selling pressure and support near $196.
LOW presents a mixed outlook: strong fundamentals and analyst support contrast with near-term technical weakness. Upside potential exists if earnings momentum continues and interest rate declines benefit home improvement spending. Key risks include revenue volatility, high debt levels, and competitive pressures. The stock's current dip may offer a buying opportunity for long-term investors, contingent on macroeconomic stability.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% today, amid a bearish technical signal and multiple class-action lawsuits alleging securities fraud. The stock shows weak fundamentals with a negative net income margin of -17.58% and ROE of -30.42%, though it beat EPS estimates in two of the last three quarters. Revenue grew to $427.54M in 2025 but profitability remains a challenge, with a high EV/EBITDA of 161.17 indicating stretched valuation relative to earnings.
Despite a 90.9% analyst buy rating and a $75.40 consensus price target, significant risks from litigation and persistent losses cloud the outlook. The stock faces near-term pressure from legal overhangs, while operational cash flow turned negative in 2026. Investors should weigh high analyst optimism against substantial fundamental and legal headwinds before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
